# Retatrutide Dosage: What Clinical Trials Studied > Retatrutide dosage ranges from Phase 1b through Phase 2 trials — study-design facts, not instructions. Retatrutide is investigational; no approved dose exists. Half-life, route, and storage in trial context. Retatrutide is investigational. There is no approved dose. These are study-design parameters from the published literature. ## First: what this page is and is not Retatrutide dosage as a clinical topic covers what doses Phase 1b and Phase 2 researchers studied, the pharmacokinetic parameters they measured, and the routes and durations the trials used. Every figure on this page is a study-design fact from the published literature — it describes what investigators administered to trial participants, not guidance for any reader. Retatrutide is not FDA-approved. No approved dose exists. No prescriber can legally prescribe it for weight management or any other indication outside a clinical trial as of 2026. Research-labeled material sold through gray-market channels carries no assurance of identity, purity, or sterility. The retatrutide dosage literature is documentation of an ongoing clinical development program — nothing more. ## Retatrutide dosage in Phase 1b and Phase 2 trials **Phase 1b (Urva et al., Lancet, 2022) [4]:** Multiple-ascending-dose design in 72 adults with type 2 diabetes over 12 weeks. Doses studied: 0.5, 1.5, 3, and escalating sequences up to 3/6/9/12 mg subcutaneous once weekly. All doses were administered by once-weekly subcutaneous injection. **Phase 2 obesity trial (Jastreboff et al., NEJM, 2023) [1]:** 338 adults with obesity. Doses: 1, 4, 8, and 12 mg subcutaneous once weekly with a structured dose-escalation period to manage GI tolerability. Duration: 48 weeks. **Phase 2 type 2 diabetes trial (Rosenstock et al., Lancet, 2023) [2]:** 281 adults. Doses: 0.5 mg to 12 mg subcutaneous once weekly with stepwise escalation over the first weeks. Duration: 36 weeks. Dose escalation (gradually increasing the dose over weeks to improve tolerability of gastrointestinal side effects) was a design feature in all trials — it is not optional context, it was the protocol. GI adverse events are dose-dependent and escalation reduces the severity by allowing tolerance to develop. ## Retatrutide half life Phase 1b pharmacokinetic data established a retatrutide half-life of approximately 6 days [4]. Half-life is the time for blood concentration to fall by half after administration. A ~6-day half-life is what supports once-weekly dosing: by day 7, enough compound remains to provide continuous receptor engagement, and steady-state concentrations are reached after approximately 4 weeks. The extended half-life is engineered: retatrutide carries a C20 fatty-diacid acyl chain (a long fat-chain modification attached to the peptide backbone) that binds reversibly to albumin (a carrier protein in blood), dramatically slowing renal clearance and extending circulation time versus an unmodified peptide. ## Route of administration in trials Every Phase 1 and Phase 2 trial studied once-weekly subcutaneous (injected into the fatty tissue beneath the skin) administration. No oral, intramuscular, or intravenous route has been studied in published retatrutide trials. The route is not a modifiable design element — it is what the approved formulation (if approved) would use, and what all published pharmacokinetic and efficacy data are derived from. ## How to reconstitute retatrutide Reconstitution instructions do not exist for retatrutide as an approved product, because it is not approved. Clinical-trial vials were manufactured by Eli Lilly to precise pharmaceutical standards — identity-verified, sterility-tested, endotoxin-screened, and concentration-verified at GMP facilities. No analogous standards apply to research-labeled gray-market material. Research-use community discussions of reconstitution describe general peptide handling practices (bacteriostatic water, slow injection into the vial, minimal agitation, refrigeration). None of these practices can compensate for unknown identity or purity in a non-pharmaceutical product. Reconstitution and injection of unverified material carries sepsis and contamination risks that clinical-trial participants, using GMP product with medical supervision, do not face. ## How to store retatrutide The clinical-trial storage conditions for pharmaceutical-grade retatrutide product are not publicly specified in the published literature. Standard peptide pharmaceutical product is typically refrigerated (2-8°C), protected from light, and has defined expiration dates — all confirmed through manufacturer stability studies that have not been performed on gray-market material. There is no published retatrutide stability data for reconstituted research-grade preparations. Storage conditions from general peptide handling guidance are not validated for this specific molecule. ## Retatrutide cost Retatrutide cost as an approved drug is unknown, because it is not approved. No commercial pricing exists as of 2026. Gray-market pricing from research chemical vendors is not reported here: this site carries no sourcing information, no pricing, and no vendor links. For context on where retatrutide sits commercially: Eli Lilly has indicated investor-day interest in this compound's commercial potential. If approved, pricing would likely track other GLP-1-class compounds, which in the US have list prices in the range of several hundred to over a thousand dollars per month before insurance. No forecast figure from this site — that determination belongs to the approval and pricing processes that come after Phase 3. ## Retatrutide availability Retatrutide availability as a prescription drug: does not exist. Clinical trial enrollment is the only legal context in which a person can access pharmaceutical-grade retatrutide under medical supervision. Gray-market research-labeled material is available through unregulated channels — the FDA's 50+ warning letters in 2025 document that market's existence and illegality. This site does not link to that market or facilitate access to it. Research-use community discussions treat retatrutide as accessible, and in a practical sense, research-labeled peptide products exist. That material is unregulated, of unverified identity and purity, and not the same as the pharmaceutical product being studied in clinical trials. ## When will retatrutide be available When will retatrutide be available as an approved drug depends on Phase 3 TRIUMPH trial results and regulatory review timelines. Phase 3 trials are ongoing as of mid-2026. If data read out in 2026 or 2027 and are submitted for regulatory review, typical FDA review timelines add 6-12 months. A realistic window for any regulatory action — assuming successful Phase 3 results and a completed submission — would not be before late 2027, and could extend further. No approval date can be stated because no submission date has been publicly announced. --- The trial record on retatrutide, read straight — investigational findings logged to source, gray-market noise filtered out, nothing here approved, prescribed, or sold.